Healthcare

Hometown NP Expands Telepsychiatry Services to 39 States Nationwide

FRANKFORT, IL / ACCESSWIRE / November 17, 2024 / Hometown NP, co-founded by Dr. Chime Ajiere, DNP, in 2023, is…

2 months ago

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life New Data…

2 months ago

Life After Hate Launches HateEraser–A Revolutionary Spray Paint Remover to Eliminate Hate-Based Graffiti

HateEraser removes hate-based graffiti in communities and gives first-time offenders a second chance through judge-mandated service NEW YORK, Nov. 16,…

2 months ago

Addressing Gender Equity and Women’s Empowerment in Underserved Communities

Boston Female Leaders Support Whittier Street Health Center's Vulnerable and Underserved Women and FamiliesBOSTON, MA / ACCESSWIRE / November 16,…

2 months ago

Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

2 months ago

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

– Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18th at 7:30 a.m.…

2 months ago

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use…

2 months ago

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit…

2 months ago

CHMP recommends RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients…

2 months ago